Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SHSE:600789'
s EV-to-FCF Range Over the Past 10 Years
Min: -575.79 Med: -14.26 Max: 559.49
Current: 16.21
During the past 13 years, the highest EV-to-FCF of Shandong Lukang Pharmaceutical Co was 559.49. The lowest was -575.79. And the median was -14.26.
SHSE:600789's EV-to-FCF is ranked better than 60.11% of 569
companies
in the Drug Manufacturers industry
Industry Median: 21.07
vs SHSE:600789: 16.21
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Shandong Lukang Pharmaceutical Co (SHSE:600789) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Shandong Lukang Pharmaceutical Co's PE Ratio (TTM) for today is calculated as:
Shandong Lukang Pharmaceutical Co's share price for today is ¥7.25.
Shandong Lukang Pharmaceutical Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥0.080.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Shandong Lukang Pharmaceutical Co EV-to-FCF Related Terms
Shandong Lukang Pharmaceutical Co EV-to-FCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Shandong Lukang Pharmaceutical Co's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shandong Lukang Pharmaceutical Co EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Shandong Lukang Pharmaceutical Co's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Shandong Lukang Pharmaceutical Co's EV-to-FCF falls into.
Shandong Lukang Pharmaceutical Co's current Enterprise Value is ¥8,167 Mil.
Shandong Lukang Pharmaceutical Co's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥504 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shandong Lukang Pharmaceutical Co (SHSE:600789) has a EV-to-FCF of 16.21 as of Jul. 23, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Shandong Lukang Pharmaceutical Co and its competitors. According to the industry distribution chart, Shandong Lukang Pharmaceutical Co ranks #227 out of 569 companies in the Drug Manufacturers industry, placing it in the top 39.9%.
Is Shandong Lukang Pharmaceutical Co's EV-to-FCF too high?
Shandong Lukang Pharmaceutical Co's current EV-to-FCF is 16.21. The Drug Manufacturers industry median EV-to-FCF is 21.07. Shandong Lukang Pharmaceutical Co's value of 16.21 is 23.1% below this industry median. Based on the distribution chart, Shandong Lukang Pharmaceutical Co ranks #227 out of 569 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Shandong Lukang Pharmaceutical Co has a GF Score™ of 67/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Shandong Lukang Pharmaceutical Co's EV-to-FCF compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Shandong Lukang Pharmaceutical Co ranks #227 out of 569 companies for EV-to-FCF. This puts Shandong Lukang Pharmaceutical Co in the upper half of its industry. The industry median EV-to-FCF is 21.07. Shandong Lukang Pharmaceutical Co's value of 16.21 is 23.1% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 21.07, based on 569 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shandong Lukang Pharmaceutical Co's current EV-to-FCF of 16.21 is 23.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Shandong Lukang Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 21.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shandong Lukang Pharmaceutical Co's current EV-to-FCF is 16.21. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shandong Lukang Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Shandong Lukang Pharmaceutical Co (SHSE:600789) is currently considered Fairly Valued. The stock's GF Value™ is ¥7.55, compared to a current price of ¥7.25 — trading 4% below its estimated fair value. The current EV-to-FCF is 16.21 and 23.1% below the Drug Manufacturers industry median of 21.07. Shandong Lukang Pharmaceutical Co's overall GF Score™ is 67/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Shandong Lukang Pharmaceutical Co (SHSE:600789), the current EV-to-FCF is 16.21 as of Jul. 23, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shandong Lukang Pharmaceutical Co (SHSE:600789) Overvalued in 2026?
Based on GuruFocus' analysis, Shandong Lukang Pharmaceutical Co stock appears to be undervalued.
The current stock price of ¥7.25 is trading 4% below its estimated GF Value™ of ¥7.55.
GuruFocus considers Shandong Lukang Pharmaceutical Co to be Fairly Valued.
Key valuation signals for SHSE:600789:
EV-to-FCF: 16.21
GF Value™: ¥7.55 vs. price of ¥7.25 (4% below fair value)
Industry Position: 23.1% below the Drug Manufacturers median (#227 of 569)
No single metric tells the full story. See the SHSE:600789 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shandong Lukang Pharmaceutical Co Business Description
Shandong Lukang Pharmaceutical Co Ltd is a bio-pharmaceuticals company. It is engaged in manufacturing antibiotics, semi-synthetic antibiotics for human use, bio-pharmaceuticals for veterinary and agriculture use, intermediates, resins, starches, glucose and amino acids.
67GF Score
Get the complete analysis for SHSE:600789
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600789 has been successfully added to your 
